Motley Fool Asset Management LLC Grows Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Motley Fool Asset Management LLC increased its holdings in Alnylam Pharmaceuticals by 217.5%, now owning 6,029 shares worth approximately $1.63 million.
• Alnylam Pharmaceuticals reported $0.32 earnings per share for the latest quarter, significantly surpassing analysts' expectations, with revenues of $773.69 million, a 17.3% year-over-year increase.
• Analyst ratings for Alnylam show strong sentiment, with 23 buy ratings and a current consensus price target of $403.92.

Motley Fool Asset Management LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 217.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,029 shares of the biopharmaceutical company's stock after acquiring an additional 4,130 shares during the quarter. Motley Fool Asset Management LLC's holdings in Alnylam Pharmaceuticals were worth $1,628,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ALNY. Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $243,000. Envestnet Asset Management Inc. lifted its position in Alnylam Pharmaceuticals by 110.5% in the 4th quarter. Envestnet Asset Management Inc. now owns 66,014 shares of the biopharmaceutical company's stock valued at $15,534,000 after acquiring an additional 34,647 shares in the last quarter. Cerity Partners LLC lifted its position in Alnylam Pharmaceuticals by 3.9% in the 4th quarter. Cerity Partners LLC now owns 13,525 shares of the biopharmaceutical company's stock valued at $3,238,000 after acquiring an additional 506 shares in the last quarter. Townsquare Capital LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $227,000. Finally, Mariner LLC boosted its stake in shares of Alnylam Pharmaceuticals by 16.6% in the 4th quarter. Mariner LLC now owns 13,666 shares of the biopharmaceutical company's stock worth $3,216,000 after buying an additional 1,947 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 2.4%

Shares of NASDAQ:ALNY traded up $10.21 during trading on Thursday, reaching $442.73. 1,263,459 shares of the company were exchanged, compared to its average volume of 952,850. The firm has a market capitalization of $58.03 billion, a PE ratio of -179.24 and a beta of 0.25. The business's fifty day simple moving average is $339.44 and its 200-day simple moving average is $287.99. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $445.20. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773,689 billion during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm's revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.13) earnings per share. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the transaction, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Piper Sandler lifted their price objective on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Raymond James Financial began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They issued an "outperform" rating and a $370.00 price target on the stock. Barclays raised their target price on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Chardan Capital lifted their target price on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. lifted their target price on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Four investment analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $403.92.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.